Inflammatory mediatorsia areo pinhibited by a taurine metabolite in CpG Oligodeoxynucleotide and IFN-r activated macrophage cell line

Journal of Drugs in Dermatology

Volumn 12, Issue 5, 2013, Pages 551-557

  Kim, Bo Sook ^a   Spinner, Daryl S ^b   Kascsak, Richard J ^b   Park, Seung Yong ^c   Cho, In Soo ^d   Schuller Levis, Georgia ^e   Park, Eunkyue ^e  

^a Seoul Grand Park Zoo   (South Korea)

^b Konkuk University   (South Korea)

^c Animal Plant and Fisheries Quarantine and Inspection Agency   (South Korea)

^d Department of Developmental Biochemistry ^*  (United States)

^e NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; NITRIC OXIDE; TAURINE; TAURINE CHLORAMINE; TOSYLCHLORAMIDE SODIUM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTACOID; CPG-OLIGONUCLEOTIDE; N-CHLOROTAURINE; OLIGODEOXYRIBONUCLEOTIDE; TLR9 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR; CPG OLIGONUCLEOTIDE; DRUG DERIVATIVE; N CHLOROTAURINE;

ALOPECIA AREATA; ARTICLE; CELL LINE; CYTOKINE RELEASE; DRUG MECHANISM; MACROPHAGE ACTIVATION; PSORIASIS; VITILIGO; ANALOGS AND DERIVATIVES; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; MACROPHAGE; METABOLISM; MOUSE; DRUG EFFECT;

ANIMALS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; MACROPHAGES; MICE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OLIGODEOXYRIBONUCLEOTIDES; RNA, MESSENGER; TAURINE; TOLL-LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84877605242     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Sturman JA. Taurine in development. Physiol. Rev. 1993;73:119-146.
2. Fudaka K, Hirai Y, Yoshida H, Hakajima T, and Ussi T. Free amino acid content of lymphocytes and granulocytes compared. Clin. Chem. 1982;28:1758-1761.
3. Wang QJ, Hollinger MA, and Giri SN. Attenuation of amiodarone-induced lung fibrosis and phospholipidosis in hamsters by taurine and/or niacin treatment. J. Pharmacol. Exp. Ther. 1992;262:127-132 .
4. Gould RE, Shaked AA, and Solan DF. Taurine protects hamster bronchioles from acute NO2 induced alterations. Am. J. Pathol. 1986;125:585-600.
5. Schuller-Levis G, Gordon R, Park E, Pendino KJ, and Laskin DL. Taurine protects rat bronchioles from acute ozone-induced lung inflammation and hyperplasia. Exp. Lung Res. 1995;21:877-888.
6. Schuller-Levis G, Gordon R, Wang C, Park S, and Park E. Protection of bleomycininduced fibrosis and inflammation by taurine. Int. Immunopharm. 2009;9:971-977.
7. Weiss SJ, Klein R, Slivka A and Wei M. Chlorination of taurine by human neutrophils. Evidence for hypochlorous acid generation. J. Clin. Invest. 1982;70:598-607.
8. Grisham MB, Jefferson MM, Melton DF, and Thomas EL. Chlorination of endogenous amines by isolated neutrophils. J. Biol. Chem. 1984;259:10404-10413.
9. Catin AM, Taurine modulation of hypochlorous acid-inducing lung epithelial cell injury in vitro, role of anion transport. J. Clin. Invest. 1994;93:606-614.
10. Kirk P and Bazan JF. Pathogen recognition: TLRs throw us a curve. Immunity 2005;23:347-350.
11. Barton GM and Medzhitov. Toll-like receptor signaling pathways. Science 2003;300:1524-1525.
12. Vollmer J. TLR9 in health and disease. Internat. Rev. Immunol. 2006;25:155-181.
13. Wilson H, Dar A, Napper SK, Lopez AM, Babiuk LA, and Mutwiri GK. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides. Internat. Rev. Immunol. 2006;25:183-213.
14. Gao JJ, Diesl V, Wittmann T, Morrison DC, Ryan JL, Vogel SN, and Follettie MT. Bacterial LPS and CpG DNA differentially induce gene expression profiles in mouse macrophages. J. Endotoxin Res. 2003;9:237-243.
15. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H. Matsunoto M, Hoshino K, Wagner H, Takeda K, and Akira S. A toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740-745.
16. Bauer S, Kirshning CJ, Hacker H, Rdecke V, Hausmann S, Akira S, Wagner H, and Lipford GB. TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. U.S.A. 2001;98:9237-9242.
17. Schaub B, Bellou A, Gibbons FK, Velasco G, Campo M, He H, Liang Y, Gillman MW, Gold D, Weiss ST, Perkins DL, Finn PW. TLR2 and TLR4 Stimulation Differentially Induce Cytokine Secretion in Human Neonatal, Adult, and Murine Mononuclear Cells. J Interferon Cytokine Res. 2004;24:543-552.
18. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Tolllike receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol. 2005;6:769-776.
19. Kawai T and Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition, Int. Immunol. 2009;21:317-337.
20. Jakob T, Walker PS, Krieg AM, Udey MC, and Vogel JC. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 response by immunostimulatory DNA. J. Immunol. 1998;161:3042-4049.
21. Sparwasser T, Miethke, T, Lipford G, Erdmann A, Hacker H, Heeg K, and Wagner H. Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. Eur. J. Immunol. 1997;27:1671-1679.
22. Klinman DM, Takeshita F, Gursel I, Leifer C, Ishii K, Verthelyi D, and Gursel M. CpG DNA: recognition by and activation of monocytes. Microbes Infect. 2002;4:897-901.
23. Park E, Quinn MR, Wright CE, and Schuller-Levis G. Taurine chloramine inhibits the synthesis of nitric oxide and the release of tumor necrosis factor in activated RAW 264.7 cells. J. Leukoc. Biol. 1993;54:119-124.
24. Park E, Schuller-Levis G, and Quinn MR. Taurine chloramine inhibits production of nitric oxide and TNF-alpha in activated RAW 264.7 cells by mechanisms that involve transcriptional and translational events. J. Immunol. 1995;154:4778-4784.
25. Kim C, Park E, Quinn MR, and Schuller-Levis GB. The production of superoxide anion and nitric oxide by cultured murine leukocytes and the accumulation of TNF-a in conditioned media is inhibited by taurine chloramine. Immunopharmacol. 1996;34:89-95.
26. Park E, Alberti J, Quinn MR, and Schuller-Levis G. Taurine chloramine inhibits lymphocyte proliferation and decrease cytokine production in activated human leukocytes. Clin. Immunol. 2002;102:179-184.
27. Quinn MR, Park E, and Schuller-Levis. Taurine chloramine inhibits prostaglandin E2 production in activated RAW 264.7 cells. Immunol. Lett. 1996;50:185-188.
28. Marcinkiewicz J, Grabowska A, Berata J and Stelmaszynska TJ. Taurine chloramine, a product of activated neutrophils, inhibits in vitro the generation of nitric oxide and other macrophage inflammatory mediators. J. Leukoc. Biol. 1995;58:667-674.
29. Park E, Levis WR, Quinn MR, Park SY, and Schuller-Levis GB. Regulation of nitric oxide induced by mycobacterial lipoarabinomannan in murine macrophages: effects of interferon-beta and taurine chloramine. Int. J. Lepr. Other Mycobact. Dis. 2000;68: 444-451.
30. Levis W, Schuller-Levis GB, and Park E. Deficient tumor necrosis factor-production in lipoarabinomannan activated macrophages from toll-like receptor- 4 deficient mice: Implication for mycobacterial susceptibility. Int. J. Leprosy 2003;71:1-9.
31. Abel B, Thieblemont N, Quesniaux VJ, Brown N, Mpagi J, Miyake K, Bihl F, and Ryffel B. Toll-like receptor 4 expression is required to control chronic Mycobacterum tuberculosis infection in mice. J Immunol. 2002;169:3155-3162.
32. Kim BS, Park SY, Cho IS, Schuller-Levis GB, Levis W, and Park E. Taurine chloramine inhibits the production of nitric oxide and TNF- in zymosan plus interferon- activated RAW 264.7 cells. J. Drugs Dermat. 2011;10:659-665.
33. Chockalingam A, Rose WA Jr, Hasan M, Ju CH, and Leifer CA. Cutting Edge: A TLR9 cytoplasmic tyrosine motif is selectively required for proinflammatory cytokine production. J. Immunol. 2012;188:527-53030.
34. Tumurkhuu G, Koide N, Daqvadori J, Noman AS, Khuda II, Naiki Y, Yoshida T, and Yokochi T. B1 cells produce nitric oxide in response to a series of toll-like receptor ligands. Cell. Immunol. 2010;251(2):122-127.
35. Capolunghi D, Eoaso MM, Cascioli S, Girolami E, Bordasco S, Vivarelli M, Ruggiero B, Cortis E, Insalaco A, Fanto N, Gallo G, Nucera E, Loiarro M, Sette C, Santis R, Carsetti R, and Ruggiero V. Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients. Reumatology 2010;49(12):2281-2289.
36. Benighni A, Caroli C, Longaretti L, Gagliardini E, Zoja C, Galbisera M, Moioli D, Romagnani P, Tincani A, Andreoli L, and Remzzi G. Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. Arthritis Rheum. 2007;56(5):1569-1578.
37. Barua M, Liu Y and Quinn MR. Taurine chloramine inhibits inducible nitric oxide synthase and TNF- gene expression in activated alveolar macrophages: decreased NF-B activation and I-B kinase activity. J. Immunol. 2002;167:2275-2281.
38. M. Sato, H. Sano, D. Iwak, K. Kudo, M. Konish, H. Takahashi, T. Takahashi, H. Imaizumi, Y. Asai, Y. Kuroki. Direct bining of toll-like-receptor 2 to zymosan, and zymosan-induced NF-B activation and TNF- secretion are down-regulatated by lung collectin surfactant protein A. J. Immunol. 2003;171:417-425.
39. Learn DB, Fried VA, Thomas EL, Taurine and hypotaurine contents of human leukocytes J. Leukoc. Biol. 1990;48;174-182.
40. Green T, Fellman JH, Eicher AL, Antioxidant role and subcellular location of hypotaurine in human neutrophils. Biochim. Biophys. Acta 1991;1073:93-97.
41. Park E, Schuller-Levis G, Jia JH Quinn MR, Preactivation exposure of RAW 264.7 cells to taurine chloramines attenuates subsequent production of nitric oxide and expression of iNOS mRNA. J. Leukoc. Biol. 1997;61:161-166.
42. Krieg AM, Love-Homan L, Yi AK, and Harty JT. CpG DNA sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J. Immunol. 1998;161:2428-2434.
43. Gramazinski RA, Doolan DL, Sedegah M, Davis HL, Krieg A. and Hoffman SL. Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotides in mice. Infect. Immun. 2001;69:1643-1649.
44. Elkins KL, Rhinehart-Jones TR, Stibitz S, Conover JS and Klinman DM. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J. Immunol. 1999;162:2291-2298.
45. Walker PS, Shcarton-Kersten T, Krieg AM, Love-Homan L, Rowton ED, Udey MC, and Vogel JC. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-dependent mechanism. Proc. Natl. Acad. Sci. U.S.A. 1999:96:6970-6975.
46. Ito S, Pedras-Vasconcelos J, and Klinman DM. CpG oligodeoxynucleotides increase the susceptibility of normal mice to infection by Candida albicans. Infect. Immun. 2005;73:6154-6156.
47. Spinner DS, Kascsak RB, LaFauci G, Meeker HC, Ye X, Flory MJ, Kim JI, Schuller-Levis GB, Levis WR, Wisniewski T, Carp RI, and Kascsak RJ. CpG oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapieassociated fibrils. J. Leukoc. Biol. 2007;81:1374-1385.
48. Klinman DM, Klaschik S, Sato T, and Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv. Drug Deliv. Rev. 2009:61(3):248-255.
49. Cho JY, Miller M, Baek KJ, Han JW, Nayar J, Rodriguez M, Lee SY. McElwain K. McElwain S, Ratz E and Broide DH. Immunostimulatory DNA inhibits transforming growth factor-beta expression and airway remodeling. Am. J. Respir. Cell Mol. Biol. 2004;30:651-661.
50. Hayashi T, Beck L, Rossetto C, Gong X, Takikawa, O, Takabayashi K, Broide DH, Carson DA, and Raz E. Inhibition of experimental asthma by indoleamine 3-dioxygenase. J. Clin. Invest. 2004;114, 270-279.
51. Auf G, Carpentier AF, Chen L, Le Clanche C, and Delattre YJ. Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen. Clin. Cancer Res. 2001;7:3540-3543.
52. Krieg AM . Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene. 2008:27(2):161-167.
53. O'Brien GC, Cahill RA, Bouchier-Hayes DJ, and Redmond HP. Co-immunotherapy with interleukin-2 and taurolidine for progressive metastatic melanoma. Ir. J. Med. Sci. 2006;175(1):1014.
54. Marcinkiewicz J, Grabowska A, and Chain BM. Modulation of antigen-specific T-cell activation in vitro by taurine chloramine. Immunology 1999;94(3):325-330.
55. Asagiri M, Hirai T, Kunigami T, Kamano S, Gober HJ, Okamoto K, Nishikawa K, Latz E, Golenbock DT, Aoki K, Ohya K, Imai Y, Morishita Y, Miyazono K, Kato S, Saftig P, and Takayanagi H. Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science 2008;319(5863):624-627.
56. Ho PP, Fontoura P, Ruiz PJ, Steinman L, and Garren H. Ab immunomodulatory CpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems. J. Immunol. 2003;171(9):4920-4926.
57. Nickerson KM, Christensen SR, Shupe J. Kashgarian M, Kim D, Elkon K and Shlomchik MJ. TLR9 regulates TRL7- and MyD88-dependent autoantibody production and disease in a murine model of lupus. J. Immunol. 2010;184:1840-1848.
58. Pawar RD, Ramanjaneyulu A, Kulkarni OP, Lech M, Segerer S, Anders HJ. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol. 2007;18:1721-31.
59. Sadana A, Nakashima H, Akahoshi M, Masutani K, Miyake K, Igawa T, Sugiyama N, Niiro H, Harada M. Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice. Arthritis Rheum. 2007;56:1618-28.
60. Vollmer J, Krieg AM, Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev. 2009;61(3):195-204.
61. Krieg AM, CpG still rocks! Update on an accidental drug. Nucleic Acid Ther. 2012;22(2):77-89.
62. Moseman EA, Liang X, Dawson AJ, Panoskaltsis-Mortari A, Krieg AM, Liu YJ, Blazar BR, Chen W. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol. 2004 1;173(7):4433-4442.
63. Volpi C, Fallarino F, Bianchi R, Orabona C, De Luca A, Vacca C, Romani L, Gran B, Grohmann U, Puccetti P, Belladonna ML.A. GpC-Rich Oligonucleotide Acts on Plasmacytoid Dendritic Cells To Promote Immune Suppression. J Immunol. 2012;189(5):2283-2289.
64. Shirota H, Klinman DM. Effect of CpG ODN on monocytic myeloid derived suppressor cells. Oncoimmunology. 2012;1(5):780-782.
65. Marcinkiewicz J. Taurine bromamine (TauBr)-its role in immunity and new perspectives for clinical use. J Biomed Sci. 2010 Aug 24;17 Suppl 1:S3. Review.